IlluminOss Medical received FDA de novo clearance for the IlluminOss Bone Stabilization System to treat pathological fractures. U.S. launch is slated for 2Q18.
K2M announced preliminary 4Q17 revenue in the range of US $67.3MM to $67.9MM, an increase of up to +10% vs. 4Q16, and full-year 2017 revenue ranging from $257.5MM to $258.1MM, +9% vs. 2016.
SeaSpine reported preliminary 4Q17 revenue in the range of US $34.2MM to $34.4MM, +5.8% vs. 4Q16, and a 2017 revenue range of $132.0MM to $132.2MM, +2.6% vs. 2016.